Chest
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The current GOLD strategy recommends combining two long-acting bronchodilators for the maintenance treatment of patients with moderate-to-severe COPD. The SHINE study evaluated the effect of QVA149, a dual bronchodilator combining the LABA indacaterol and the LAMA glycopyrronium (NVA237), compared with glycopyrronium, indacaterol, tiotropium monotherapies and placebo. ⋯ Kenneth Chapman: Consultant fee, speaker bureau, advisory committee, etc.: "KRC holds the GSK-CIHR Research Chair in Respiratory Healthcare Delivery at the University Health Network, has served as a consultant to CSL Behring, GlaxoSmithKline, Novartis, Nycomed (Takeda), and Talecris (Grifols), and has received payment for lectures or service on speakers bureaus from Boehringer-Ingelheim, GlaxoSmithKline, Grifols, Nycomed (Takeda), Family Physicians Airways Group of Canada, Canadian Network for Respiratory Care, and Talecris. " Eric Bateman: Consultant fee, speaker bureau, advisory committee, etc.: Prof Eric Bateman has served on advisory boards for Boehringer Ingelheim, AstraZeneca, Elevation Pharma, Napp Pharma, Novartis, Almirall, Forest, and Merck and Takeda; has served as a consultant to Navigant Consulting, IMS consulting group, ALK-Abello, Almirall, Hoffman la Roche, and ICON; has been paid lecture fees by AstraZeneca, ALK-Abello, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Nycomed/Takeda, Novartis, Pfizer, and Indegene Lifesciences Ltd. Nicola Gallagher: Employee: Novartis employee Huilin Hu: Employee: Novartis employee Donald Banerji: Employee: Novartis employeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Infectious Disease Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The Milwaukee Protocol was used for a 24 year-old male U.S. soldier who was diagnosed with rabies after being bit by a feral dog in Afghanistan. He did not receive effective post exposure prophylaxis (PEP) for rabies however [1]. ⋯ Our case highlights the first time ECMO was used in rabies. Also, it exemplifies another failed case of the Milwaukee Protocol. Given the lack of efficacy, the protocol should not be used for rabies. A better understanding of rabies pathogenesis is needed in order to develop novel therapies.Reference #1: Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Res. 2013 Jul;99(1):61-7.Reference #2: Willoughby,R et. Al Survival after Treatment of Rabies with Induction of Coma, N Engl J Med2005; 352:2508-2514DISCLOSURE: The following authors have nothing to disclose: Amritpal Nat, Amitpal Nat, Amit Sharma, Aravind Pothineni, Ioana AmzutaNo Product/Research Disclosure Information.
-
Lung Cancer Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Half of non-small cell lung cancers are diagnosed in locally advanced stages (LA-NSCLC) and treated by combining chemotherapy, radiation (RT), and surgery (S). Induction chemo (iCT) and chemoradiation (iCRT) are at least as effective as adjuvant therapies are, and allow to infer survival predictions depending on the grade of response. The 18-FDG-PET-CT-Scan (PET) is slowly introducing in the evaluation of those responses. We analyzed the impact of changes in re-staging PET in the outcome of patients with LA-NSCLC treated with induction therapies ⋯ Diego Marquez-Medina: Grant monies (from industry related sources): Llilly advisor, Grant monies (from industry related sources): Roche advisor, Grant monies (from industry related sources): Astra Zeneca speacher The following authors have nothing to disclose: Ariadna Gasol-Cudos, Antonio Martin-MarcoNo Product/Research Disclosure Information.
-
PleuralSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: Study objective: To evaluate the role of rigid medical thoracoscopy in the management of patients with undiagnosed exudative pleural effusion. ⋯ The following authors have nothing to disclose: Essam Hassanein, Eman Hatata, Suzan Helal, Emad Ibrahim, Ayman BaessNo Product/Research Disclosure Information.
-
DVT/PE PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Although fondaparinux is recommended by experts for the treatment of heparin- induced thrombocytopenia (HIT), recent guidelines from the American College of Chest Physicians do not support its use. In light of the aforementioned uncertainties, we conducted a systematic review to assess outcomes in HIT patients treated with fondaparinux. ⋯ The following authors have nothing to disclose: Catherine Ivory, Gregoire Le Gal, Marc Carrier, Marc Rodger, Catherine Code, Esteban GandaraNo Product/Research Disclosure Information.